Riofast (Tablets, Suspension) Instructions for Use

ATC Code

A02AD02 (Magaldrate)

Active Substance

Magaldrate (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Antacid drug

Pharmacotherapeutic Group

Antacid agent

Pharmacological Action

Antacid agent. It neutralizes hydrochloric acid in the stomach and reduces the activity of pepsin.

It has an adsorbing and enveloping effect. It prevents the influence of aggressive factors on the gastric mucosa and enhances its own protective mechanisms, does not change the physiology of digestion and does not cause reactive secretion of hydrochloric acid.

Pharmacokinetics

Absorption from the gastrointestinal tract is low.

Indications

Acute gastritis; chronic gastritis with increased and normal secretory function of the stomach (in the acute phase); acute duodenitis; gastric ulcer and duodenal ulcer (in the acute phase); symptomatic ulcers of various origins; erosions of the gastrointestinal mucosa; reflux esophagitis; hiatal hernia; gastralgia, heartburn (after excessive consumption of ethanol, nicotine, coffee, medication use, dietary errors); dyspepsia of neurotic origin.

ICD codes

Dosage Regimen

Determine the dosage individually based on the clinical presentation and gastric acidity.

For tablets, chew thoroughly or allow to dissolve in the mouth before swallowing.

For the suspension, shake the bottle vigorously immediately before each use to ensure uniform consistency.

Administer a single dose of 0.8 grams to 1.6 grams (equivalent to 800 mg to 1600 mg of magaldrate).

Take the medication 1 to 2 hours after each meal and at bedtime, typically 3 to 4 times per day.

For the management of nocturnal heartburn, a single dose at bedtime may be sufficient.

Do not exceed the maximum daily dose of 5.6 grams (5600 mg) of magaldrate.

The duration of treatment depends on the indication and therapeutic response; do not use for prolonged, continuous therapy without medical supervision.

For symptomatic relief of occasional heartburn or dyspepsia, use only as needed.

Maintain an interval of at least 2 hours between the intake of magaldrate and any other oral medication to prevent potential drug interactions.

Adverse Reactions

Possible nausea, vomiting, constipation, diarrhea.

With long-term use in high doses, possible hypophosphatemia, hypocalcemia, hypercalciuria, osteomalacia, osteoporosis, hypermagnesemia, hyperaluminemia, encephalopathy, nephrocalcinosis, impaired renal function.

In patients with concomitant renal failure, possible thirst, decreased blood pressure, decreased reflexes.

Contraindications

Chronic renal failure, Alzheimer’s disease, hypophosphatemia, pregnancy, hypersensitivity to magaldrate.

Use in Pregnancy and Lactation

Magaldrate is contraindicated for use during pregnancy.

During lactation (breastfeeding), Magaldrate should be used with caution.

Use in Renal Impairment

Contraindicated in chronic renal failure.

With long-term use of magaldrate in patients with impaired renal function, regular monitoring of plasma aluminum levels should be performed.

Pediatric Use

Use with caution in children under 12 years of age.

Special Precautions

With long-term use of magaldrate in patients with impaired renal function, regular monitoring of plasma aluminum levels should be performed.

Use with caution in children under 12 years of age.

Drug Interactions

With simultaneous oral administration, Magaldrate may impair the absorption of tetracyclines, iron preparations, bile acid preparations, digoxin, benzodiazepines, dicumarol, indomethacin, cimetidine, isoniazid, quinolone derivatives (ciprofloxacin, ofloxacin, norfloxacin).

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.